Targeting the Dopaminergic Pathway: Evolving Approaches in Parkinson Disease

A panelist discusses how adjunctive therapies in Parkinson disease optimize and sustain dopamine levels in the central nervous system through various mechanisms of action that complement levodopa therapy.

A panelist discusses how current FDA-approved dopamine agonists (DAs), which primarily target D2 and D3 receptors, present a complex clinical challenge due to the need to balance their efficacy with a notable risk of adverse events.

A panelist discusses how tavapadon’s D1/D5 receptor selectivity may offer potential benefits such as improved motor symptom control with a reduced risk of adverse effects commonly associated with traditional dopamine agonists.

A panelist discusses how partial vs full activation of D1/D5 receptors can differentially influence downstream signaling pathways, potentially leading to more favorable clinical outcomes with fewer adverse effects in Parkinson disease treatment.

A panelist discusses how efficacy data from the TEMPO clinical trials suggest that tavapadon demonstrates promising benefits as both a monotherapy and adjunctive therapy to levodopa in adults with Parkinson disease.

A panelist discusses how tavapadon’s safety profile may offer advantages over higher doses of levodopa and traditional D2/D3 dopamine agonists by potentially reducing the incidence of dose-related adverse effects while maintaining symptom control.